Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
What a very appropriate name. Nano= very small / Synth = synthetic.
Quite how this company continues to command a valuation of £26m is beyond me.
Robin Hood is depressed. His old method of people keeping hold of their entitlements & waging war against robber barons such as the Sherriff of Nottingham just ain't working anymore.
Now the message is: "Take from the poor - give to the rich"
Yes, total shafting & a virtually criminal disgrace.
Do we need any better example of how the system is rigged against PI's .
Too often, advisors, paid by the company [ie existing shareholders] seem to be working hand-in-glove with new investors to drive prices of new funding down.
Yes, certainly material &, might one say, a SUPER deal !
At last the fundamental value within Adriatic is being recognized.
As for anyone who takes their info from Hargreaves Lansdown they show the market cap as £580 which is actually the A$ cap.
There are 209m shares in issue = a cap @ £1.50 of some £313.
I continue to believe that this is a quality mid-cap mining company in the making.
If there's a decent turn
the placees will churn.
SIMPLE.
So expect a material drop in the share price. Whether this represents a good opportunity for averaging down or as a new entry point very much depends upon your view of the fundamental attractions of HEMO's scientific base.
Read through from Bacconora marks Ironridge out as being cheap - particularly post fundraising.
And then of course you have the gold.
Underappreciated by the market but that will change.
Patient holders take comfort.
This deal is going down like a lead balloon in America where they could be expected to understand the merits / demerits of Chiasma.
Post close Nasdaq price of $11,03 per ADR = some £1,59 UK per share.
Not good.
Read today's RNS just to update my memory bank. This company exudes quality & i suspect that any buyer at this level will be handsomely rewarded over time.
I like to think that I do not have criminal tendencies but I have been tempted this morning.
In reply to the comments concerning dilution I would only say that you do not build a major pharma company without investment just as you cannot make an omelette without breaking eggs.
A confident fundraise at a minimal discount.
"Now funded to profitability" for the cortisol franchise.
Diurnal has all the hallmarks of a quality & sure-footed company.
.... than those that cannot see.
IMO the progress of the company under JW has been mightily impressive up to now - most particularly in building a fabrication & ship maintenance business with a range of operational assets unrivalled in the UK & standing well within the upper echelons of the European league.
Rome was not built in a day but the foundation stones have been well laid & every month that passes the walls get higher.
The potential here is enormous. Of course this will not be fully realized without further financing and in this regard I personally would be tempted by that neglected instrument, the Convertible Preference. Once common but now rarely seen.
Also, as the company grows, the company's assets [already having a replacement value many times greater than Infras market cap] will be seen to have a much greater tangible value and potential for secured borrowing.
"Please lock me away" as that pop duo of the 1960's famously crooned.
This is a virtually moribund board - why I do not know. I guess that is there were 100 times more shares in issue & the sp was 1.25p then PI's would be all over it.
So, in the belief that this is a major mid-cap miner in the making I am taking my cue from the pop duo of the 1960's, "Peter & Gordon" & taking the opportunity to lock ADR's shares away.
No, tony: Not referenced in the RNS.
The .0001 is merely the nominal value of the shares in issue. Admittedly they cannot, by law, issue shares below this level but it tells us nothing of the actual exercise price of these warrants.
So no option other than to spend time ascertaining info that should be clearly stated.
Re: RNS - So what were these 6.7m warrants exercised at ? Why not tell us - it should not be necessary for PI's to delve back into past reports to ascertain this rather important detail !
Also, should it not be established good practice, whenever warrants are exercised to state the amount of warrants & exercise prices of all remaining unexercised warrants.
It is known as providing the owners of the business will full information.
Does the late reported sale of 191,796 on 14 April represent the final clearing of the stock overhang ?
Let us hope so & that we can look forward to a steady rerating.
Quite agree laveonews:
In my opinion a significant re-rate is beginning. This is a company that exits the pandemic period in a stronger position than it entered it. Clearly there has been a stock overhang that looks as though it is close to being cleared.
IMO a buy & long tern hold.
....... can go up as well as down.
Genedrive is a technology rich company but will it ever achieve meaningful revenues & profitability?
On this measure, i think, the jury is still out.
As investors including institutions start to take full note of the depth of IP in Deepverge, which is growing month by month, they will realise that this company is far more than a 'one trick pony'.
Which makes it, to my mind, a buy & long-term hold